Abbott Laboratories

ABT Health Care Market cap $178B as of Sep 14, 2026 16:03 ET S&P 500

Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 29, 2026

Revenue$11.16B +8% year over year

Gross profit$6.27B 56% margin

Operating profit$1.35B 12% margin

Net profit$1.08B 10% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	11.16	100%	+8%
Medical devices	5.54	50%	+13%
Diagnostic products	2.18	19%	+6%
Nutritional products	2.02	18%	−6%
Established pharmaceutical	1.43	13%	+13%
Cost of revenue	−4.89	44%
Gross profit	6.27	56% margin	−1pp
R&D	−0.77	7%	+0pp
SG&A	−3.74	33%	+4pp
Other	−0.42	4%	+0pp
Operating profit	1.35	12% margin	−4pp
Other income, net	0.10
Tax	−0.37
Net profit	1.08	10% margin	−3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	11.46	100%	+4%
Medical devices	5.68	50%	+12%
Diagnostic products	2.46	21%	−2%
Nutritional products	1.94	17%	−9%
Established pharmaceutical	1.38	12%	+9%
Cost of revenue	−4.92	43%
Gross profit	6.54	57% margin	+2pp
R&D	−0.74	6%	+0pp
SG&A	−3.13	27%	+1pp
Other	−0.42	4%	+0pp
Operating profit	2.25	20% margin	+2pp
Other income, net	0.11
Tax	−0.58
Net profit	1.78	15% margin	−69pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	11.37	100%	+7%
Medical devices	5.45	48%	+15%
Diagnostic products	2.25	20%	−7%
Nutritional products	2.15	19%	+4%
Established pharmaceutical	1.51	13%	+7%
Cost of revenue	−5.08	45%
Gross profit	6.29	55% margin	+0pp
R&D	−0.77	7%	+0pp
SG&A	−3.05	27%	+0pp
Other	−0.42	3%	+0pp
Operating profit	2.06	18% margin	+1pp
Other income, net	0.12
Tax	−0.54
Net profit	1.64	14% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	11.14	100%	+7%
Medical devices	5.37	48%	+13%
Nutritional products	2.21	20%	+3%
Diagnostic products	2.17	20%	−1%
Established pharmaceutical	1.38	12%	+7%
Cost of revenue	−4.85	44%
Gross profit	6.29	56% margin	+1pp
R&D	−0.73	6%	+0pp
SG&A	−3.09	28%	−1pp
Other	−0.42	4%	+0pp
Operating profit	2.05	18% margin	+2pp
Other income, net	0.10
Tax	−0.37
Net profit	1.78	16% margin	+3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 29, 2026 Operating margin 12% Net profit $1.08B	Jan 1 – Mar 31, 2026	Apr 29, 2026	$11.2B	+8%	12%	$1.08B	10%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 20, 2026 Operating margin 20% Net profit $1.78B	Oct 1 – Dec 31, 2025	Feb 20, 2026	$11.5B	+4%	20%	$1.78B	15%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 29, 2025 Operating margin 18% Net profit $1.64B	Jul 1 – Sep 30, 2025	Oct 29, 2025	$11.4B	+7%	18%	$1.64B	14%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Jul 30, 2025 Operating margin 18% Net profit $1.78B	Apr 1 – Jun 30, 2025	Jul 30, 2025	$11.1B	+7%	18%	$1.78B	16%